Who are Margenza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Enhertu, Kadcyla, Perjeta, Gleevec, MARGENZA, OGIVRI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/margetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Margenza — Competitive Intelligence Brief

Margenza (MARGETUXIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2/neu Receptor Antagonist [EPC]. Area: Oncology.

marketed HER2/neu Receptor Antagonist [EPC] Receptor tyrosine-protein kinase erbB-2 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Margenza (MARGETUXIMAB) — Macrogenics Inc. Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Margenza TARGET	MARGETUXIMAB	Macrogenics Inc	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2020-01-01
Enhertu	trastuzumab-deruxtecan	Daiichi Sankyo	marketed		Receptor tyrosine-protein kinase erbB-2	2019-01-01
Kadcyla	trastuzumab-emtansine	Roche	marketed	Antibody-drug conjugate	Receptor tyrosine-protein kinase erbB-2	2013-01-01
Perjeta	pertuzumab	Roche	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2012-01-01
Gleevec	imatinib	Novartis	marketed	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
MARGENZA	MARGETUXIMAB-CMKB	MACROGENICS INC	marketed	HER2/neu Receptor Antagonist [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2
OGIVRI	TRASTUZUMAB-DKST	MYLAN GMBH	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2

Recent regulatory actions (last 90 days)

2026-03-26 — Kadcyla · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2/neu Receptor Antagonist [EPC] class)

AMGEN INC · 1 drug in this class
CELLTRION INC · 1 drug in this class
MACROGENICS INC · 1 drug in this class
MYLAN GMBH · 1 drug in this class
Macrogenics Inc · 1 drug in this class
Roche · 1 drug in this class
SAMSUNG BIOEPIS CO LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Margenza — Competitive Intelligence Brief. https://druglandscape.com/ci/margetuximab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab